E-cadherin as a predictive marker of brain metastasis in nonsmallcell lung cancer, and its regulation by pioglitazone in a preclinical model

Journal of Neuro-Oncology

Volumn 109, Issue 2, 2012, Pages 219-227

  Yoo, Jin Young ^a   Yang, Seung Ho ^a   Lee, Jung Eun ^a   Cho, Deog Gon ^a   Kim, Hoon Kyo ^a   Kim, Sung Hwan ^a   Kim, Il Sup ^a   Hong, Jae Taek ^a   Sung, Jae Hoon ^a   Son, Byung Chul ^a   Lee, Sang Won ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Biomarker; Brain metastasis; E cadherin; NSCLC; PPARC ; Prevention

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; DEATH ASSOCIATED PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; GELATINASE B; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PIOGLITAZONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UVOMORULIN; VASCULOTROPIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; CANCER CELL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTION; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN METHYLATION; REGULATORY MECHANISM;

AGED; ANIMALS; BRAIN; BRAIN NEOPLASMS; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIC AGENTS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MIDDLE AGED; ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; THIAZOLIDINEDIONES; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866036117     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0890-8     Document Type: Article

References (45)

1. Jemal A, Siegal R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics 2008. CA Cancer J Clin 58:71-96
2. Robnett TJ, Machtay M, Stevenson JP, Algazy KM, Hahn SM (2001) Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol 19:1344-1349 (Pubitemid 32202539)
3. Arnold SM, Young AB, Munn RK, Patchell RA, Nanayakkara N, Markesbery WR (1999) Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. Clin Cancer Res 5:4028-4033 (Pubitemid 30013780)
4. D'Amico TA, Aloia TA, Moore MB, Conlon DH, Herndon JE 2nd, Kinch MS, Harpole DH Jr (2001) Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 72:1144-1148 (Pubitemid 32937993)
5. Milas I, Komaki R, Hachiya T, Bubb RS, Ro JY, Langford L, Sawaya R, Putnam JB, Allen P, Cox JD, McDonnell TJ, Brock W, Hong WK, Roth JA, Milas L (2003) Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small-cell lung cancer and brain metastases. Clin Cancer Res 9:1070-1076 (Pubitemid 36323713)
6. Petersen I, Hidalgo A, Petersen S, Schlüns K, Schewe C, Pacyna-Gengelbach M, Goeze A, Krebber B, Knösel T, Kaufmann O, Szymas J, von Deimling A (2000) Chromosomal imbalances in brain metastases of solid tumors. Brain Pathol 10:395-401 (Pubitemid 30431292)
7. Esteller M, Herman JG (2004) Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 23:1-8 (Pubitemid 38142234)
8. Li H, Lindenmeyer F, Grenet C, Opolon P, Menashi S, Soria C, Yeh P, Perricaudet M, Lu H (2001) AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther 12:515-526 (Pubitemid 32511073)
9. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Bavlin SB, Graff JR (1999) Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59:798-802 (Pubitemid 29086729)
10. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A (1995) Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferoninduced cell death. Genes Dev 9:15-30
11. Thunnissen FB, Schuurbiers OC, den Bakker MA (2006) A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology 48:779-786 (Pubitemid 43800936)
12. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittelman WN, Hong WK (1995) Expression of p53 oncoprotein in nonsmallcell lung cancer: a favorable prognostic factor. J Clin Oncol 13:1893-1903
13. Koomägi R, Volm M (2000) Relationship between the expression of caspase-3 and the clinical outcome of patients with non-smallcell lung cancer. Anticancer Res 20:493-496 (Pubitemid 30189707)
14. Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT, Bremnes RM (2007) Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 13:6649-6657 (Pubitemid 350206800)
15. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37:S9-S15 (Pubitemid 32938124)
16. Yilmaz M, Christonfori G (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28:15-33
17. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owen RJ, Lang NP (2007) Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476-1481 (Pubitemid 46733074)
18. Choudhary R, Li H, Winn RA, Sorenson AL, Weiser-Evans MC, Nemenoff RA (2010) Peroxisome proliferator-activated receptorc inhibits transformed growth of non-small-cell lung cancer cells through selective suppression of snail. Neoplasia 12:224-234
19. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ (2004) Peroxisome proliferatoractivated receptor-c activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23:100-108 (Pubitemid 38142244)
20. Lyon CM, Klinge DM, Do KC, Grimes MJ, Thomas CL, Damiani LA, March TH, Stidley CA, Belinsky SA (2009) Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis 30:2095-2099
21. Reddy RC, Srirangam A, Reddy K, Chen J, Gangireddy S, Kalemkerian GP, Standiford TJ, Keshamouni VG (2008) Chemotherapeutic drugs induce PPAR-c expression and show sequencespecific synergy with PPAR-c ligands in inhibition of non-smallcell lung cancer. Neoplasia 10:597-603 (Pubitemid 351770303)
22. Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, Berthe ML, Noël D, Pillon A, Iborra F, Dubus P, Maudelonde T, Culine S, Fajas L (2006) Peroxisome proliferator-activated receptor c regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 26:7561-7574 (Pubitemid 44547706)
23. Yang SH, Lee KS, Yang HJ, Jeon BH, Lee YS, Nam SW, Chung DS, Lee SW, Hong YK (2011) O (6)-methylguanine-DNAmethyltransferase promoter methylation assessment by microdissectionassisted methylation-specific PCR and high resolution melting analysis in patients with glioblastomas. J Neurooncol 27. doi:10.1007/s11060-011-0668-4
24. Bubb RS, Komaki R, Hachiya T, Milas I, Ro JY, Langford L, Sawaya R, Putnam JB, Allen P, Cox JD, McDonnell TJ, Brock W, Hong WK, Roth JA, Milas L (2002) Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion. Int J Radiat Oncol Biol Phys 53:1216-1224 (Pubitemid 34787858)
25. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ (2000) Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 60:1453-1459
26. Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR (2010) Factors associated with the development of brain metastases: analysis of 975 patients with early stage non-small-cell lung cancer. Cancer 116:5038-5046
27. Prudkin L, Liu D, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C, Wistuba II (2009) Epithelialtomesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol 22:668-678
28. Leber MF, Efferth T (2009) Molecular principles of cancer invasion and metastasis. Int J Oncol 34:881-895
29. Shabani HK, Kitange G, Tsunoda K, Anda T, Tokunaga Y, Shibata S, Kaminogo M, Hayashi T, Ayabe H, Iseki M (2003) Immunohistochemical expression of E-cadherin in metastatic brain tumors. Brain Tumor Pathol 20:7-12 (Pubitemid 36851075)
30. Saad AG, Yeap BY, Thunnissen FB, Pinkus GS, Pinkus JL, Loda M, Sugarbaker DJ, Johnson BE, Chirieac LR (2008) Immunohistochemical markers associated with brain metastasis in patients with non-small cell lung carcinoma. Cancer 113:2129-2138
31. Nernenoff RA (2007) Peroxisome proliferator-activated receptorgamma in lung cancer: defining specific versus "off-target" effectors. J Thorac Oncol 2:989-992
32. Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, Keshamouni VG (2010) Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 9:3221-3232
33. Han C, Demetris AJ, Liu Y, Shelhamer JH, Wu T (2004) Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE) 2/EP1 and peroxisome proliferator-activated receptorgamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-betainduced mitoinhibition. J Biol Chem 279:44344-44354
34. Davies M, Robinson M, Smith E, Huntley S, Prime S, Paterson I (2005) Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem 95:918-931 (Pubitemid 41420140)
35. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68:3645-3654
36. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, Varga J (2009) Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 23:2968-2977
37. Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA, Mazzarino C (2009) Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol 34:897-903
38. Jia D, Yan M, Wang X, Hao X, Liang L, Liu L, Kong H, He X, Li J, Yao M (2010) Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC Cancer 10:364
39. Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G, Sullivan PG (2011) Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol 227:128-135
40. Thal SC, Heinemann M, Luh C, Pieter D, Werner C, Engelhard K (2011) Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-c-independent mechanisms. J Neurotrauma 28:983-993
41. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP (2003) Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 79:391-397 (Pubitemid 36750946)
42. Yee LD, Williams N, Wen P, Young DC, Lester J, Johnson MV, Farrar WB, Walker MJ, Povoski SP, Suster S, Eng C (2007) Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 13:246-252 (Pubitemid 46121876)
43. Girnun GD, Chen L, Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, Li D, Force J, McNamara K, Demetri G, Spiegelman BM, Wong KK (2008) Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 14:6478-6486
44. Shimizu M, Moriwaki H (2008) Synergistic effects of PPARgamma ligands and retinoids in cancer treatment. PPAR Res 2008:181047
45. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65:9455-9462 (Pubitemid 41508014)